Use of prescription drug-monitoring programs (PDMPs) has increased significantly in recent years, but information gaps remain, a problem that new AMA policy adopted at the 2017 AMA Annual Meeting seeks to address. …
“Use will go up when they become more useful tools,” Dr. McAneny (@BarbaraMcAneny) said while presenting a Board of Trustees report to the reference committee.